Current Headlines

  1. Jnana Therapeutics Enters Collaboration With Roche To Discover Novel Medicines That Target Key Regulators Of Cellular Metabolism To Treat Immune-Mediated And Neurological Diseases 7/21/2020

    Jnana Therapeutics today announced a strategic, multi-target collaboration and license agreement with Roche for the discovery of small molecule drugs directed at the solute carrier (SLC) family of metabolite transporters as a broad, innovative approach for modulating cellular metabolism to treat immune-mediated and neurological diseases

  2. Cognizant Shared Investigator Platform For Life Sciences Reaches Major Milestone In Accelerating Drug Discovery 7/21/2020

    Cognizant (Nasdaq: CTSH) announced that its Shared Investigator Platform (SIP), a life sciences Software as a Service (SaaS) solution, has reached a new milestone of over 100,000 users in 84 countries

  3. Samsung Biologics Expands Drug Product Manufacturing Facility In Incheon 7/20/2020

    Samsung Biologics (207940.KS) announced a plan to expand its Drug Product (DP) capability in line with increasing market demand and to ensure flexible production capabilities for new and existing clients

  4. Invetx Announces Industry-Leading Antibody Discovery Platform To Develop Portfolio Of Novel Therapeutics For Animal Health 7/16/2020

    Invetx, a pioneer in protein-based therapeutics for animal health, announced today the launchof its antibody-based platform for the discovery and development of novel medicines for animal health

  5. New Early Breast Cancer Drug Now Approved In Malaysia 7/16/2020

    A NEW breast cancer drug shown to significantly reduce the risk of cancer recurrence is now approved for use in Malaysia.

  6. FDA Grants Priority Review To Merck’s New Drug Application For Vericiguat 7/16/2020

    Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has accepted for priority review the New Drug Application (NDA) for vericiguat, an orally administered soluble guanylate cyclase (sGC) stimulator, to reduce the risk of cardiovascular death and heart failure hospitalization following a worsening heart failure event in patients with symptomatic chronic heart failure with reduced ejection fraction (HFrEF), in combination with symptomatic chronic heart failure with reduced ejection fraction (HFrEF), in combination with other heart failure therapies

  7. NeoImmuneTech Announces Clearance For Investigational New Drug Application Of NT-I7 (Efineptakin Alfa) In Adults With Mild COVID-19 7/15/2020

    NeoImmuneTech, Inc., a clinical-stage T cell-focused biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application to study the use of NT-I7 (efineptakin alfa), a long-acting human IL-7, for the treatment of adults with mild COVID-19.

  8. Mallinckrodt Announces U.S. Food And Drug Administration (FDA) Advisory Committee Voted To Recommend Terlipressin For Approval To Treat Patients With Hepatorenal Syndrome Type 1 (HRS-1) 7/15/2020

    Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced that the Cardiovascular and Renal Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) voted to recommend approval for its investigational agent terlipressin to treat adults with hepatorenal syndrome type 1 (HRS-1) (8 yes; 7 no)

  9. Doctor Evidence To Deploy Its AI-Enabled SaaS DOC Search And DOC Analytics Platform For COVID-19 To Accelerate Drug Discovery 7/14/2020

    Doctor Evidence (“DRE”) has developed new tools for automated network meta-analysis, to now be used in the hunt for the most effective treatments for COVID-19. Clinical trial data is continuously emerging that can now be aggregated in real time using DRE’s DOC Analytics platform

  10. TREMFYA® (Guselkumab) Approved By U.S. Food and Drug Administration As The First Selective Interleukin (IL)-23 Inhibitor For Active Psoriatic Arthritis 7/14/2020

    The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved TREMFYA® (guselkumab) for adult patients with active psoriatic arthritis (PsA), a chronic progressive disease characterized by painful joints and skin inflammation.1,2 TREMFYA is the first treatment approved for active PsA that selectively inhibits interleukin (IL)-23, a naturally occurring cytokine that is involved in normal inflammatory and immune responses associated with the symptoms of PsA